Annexin Pharmaceuticals AB (publ) has entered into a license agreement with Stanford University, CA, USA granting Annexin Pharmaceuticals exclusive license to patent rights related to use of Annexin A5 in treatment of cancer. The license involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals' drug candidate ANXV. Studies have shown that Annexin A5 acts as a potent immunomodulating anti-cancer agent acting via blocking phosphatidylserine (PS) on cancer cells (US patent No 11,253,568).